Using Addiction Comprehensive Health Enhancement Support System (ACHESS) in an Alcoholic Liver Disease Population


This is a pilot study examining whether an evidence-based recovery support smartphone application, the Addiction Comprehensive Health Enhancement Support System (A-CHESS), can decrease alcohol recidivism in a previously unstudied group of patients with alcoholic liver disease (ALD).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Health Services Research
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 15, 2021

Detailed Description

A-CHESS is a smartphone application developed by the University of Wisconsin-Madison based on self-determination theory, with a previous randomized clinical trial showing that use of the app resulted in significantly fewer risky drinking days in patients leaving treatment for alcohol-use disorders. The application is downloaded to the participant's smartphone, and provides ongoing access to peer support and educational materials, monitoring of the risk of relapse, and delivery of reminders and encouragements to the patient. The application also has a survey platform to assess and reassess the participants' most recent alcohol consumption, quality of life, and experience using the application. We anticipate that use of the A-CHESS app will result in decreased drinking and improved abstinence, identifying a potential intervention to offer patients with ALD to improve their mortality, liver disease, and likelihood of liver transplant candidacy status.


  • Device: A-CHESS
    • Use of smartphone application: Addiction Comprehensive Health Enhancement Support System (A-CHESS)

Arms, Groups and Cohorts

  • Experimental: Participants receiving A-CHESS
    • Participants will be provided access to the smartphone application A-CHESS (intervention) that will be downloaded to their phone.

Clinical Trial Outcome Measures

Primary Measures

  • Rates of recidivism
    • Time Frame: 6 months
    • Rates of recidivism in this population using A-CHESS will be compared to historical control rates

Secondary Measures

  • Use of A-CHESS
    • Time Frame: 6 months
    • The association between the extent to which patients use the A-CHESS application and their recidivism; to compare use of the A-CHESS app among subjects who drink and remain abstinent.

Participating in This Clinical Trial

Inclusion Criteria

  • Alcoholic liver disease – Followed or seen at New York Presbyterian Hospital / Weill Cornell Medical Center – English speaking – Access to a smartphone Exclusion Criteria:

  • Unable to consent – Primary language other than English – No access to a smartphone

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • New York Presbyterian Hospital
  • Collaborator
    • University of Wisconsin, Madison
  • Provider of Information About this Clinical Study
    • Principal Investigator: Nicole T Shen, Principal Investigator – New York Presbyterian Hospital
  • Overall Official(s)
    • Robert S Brown, MD, MPH, Principal Investigator, Weill Cornell Medical College/NYPH
  • Overall Contact(s)
    • Nicole T Shen, MD, 3146095911,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.